Symbiotec Pharmalab IPO Day 1: Subscription Status, Timeline & Key Issue Details
Symbiotec Pharmalab's ₹1,757.0 crore initial public offering (IPO) opened for public subscription today, August 24, 2026, with a price band of ₹938 to ₹988 per share. As of 10:05 A.M on the first day of bidding, the issue had been subscribed 0.01 times.
The IPO will remain open for subscription until 27 August 2026. The basis of allotment is expected to be finalised on 28 August 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on 1 September 2026.
Symbiotec Pharmalab IPO - Issue Details
- Issue Type: Book Built Issue (Fresh Issue + OFS)
- Total Issue Size: Up to ₹1,757.00 crore
- Fresh Issue: Up to ₹150.00 crore
- Offer for Sale (OFS): Up to ₹1,607.00 crore
- Face Value: ₹2 per equity share
- Price Band: ₹938 to ₹988 per share
- Lot Size: 15 shares
- Minimum Investment Amount (Retail Investor): ₹14,820 (15 shares at the upper price)
- Listing: BSE, NSE
- Book Running Lead Managers: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory and Securities (India) Private Limited
- Registrar: MUFG Intime India Private Limited
Symbiotec Pharmalab IPO Timeline (Tentative)
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
24 August 2026 |
|
Subscription Closing Date |
27 August 2026 |
|
Basis of Allotment Date |
28 August 2026 |
|
Refund Initiation Date |
31 August 2026 |
|
Credit of Shares |
31 August 2026 |
|
Listing on BSE and NSE |
1 September 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
Symbiotec Pharmalab IPO Day 1 Subscription Status
[August 24, 2026, 10:05 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.00x |
|
Non-Institutional Investors (NIIs) |
0.01x |
|
Retail Individual Investors (RIIs) |
0.01x |
|
Total |
0.01x |
Utilisation of IPO Proceeds
The company intends to utilise the net proceeds from the fresh issue towards:
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
- General corporate purposes.
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is an R&D-focused pharmaceutical and biotechnology company specialising in organic chemistry, biotechnology, and complex injectables. It is a global leader in corticosteroid and steroidal-hormone APIs by volume and offers a portfolio of over 60 APIs for regulated pharmaceutical markets.
The company operates a vertically integrated manufacturing platform with API, fermentation, and injectable facilities in Madhya Pradesh. It also provides CDMO services to global pharmaceutical and nutraceutical companies, supported by multiple international regulatory approvals.
Key Financial Highlights
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
869.15 |
751.55 |
716.25 |
|
EBITDA |
231.97 |
206.11 |
177.04 |
|
Profit After Tax (PAT) |
109.90 |
96.79 |
100.05 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here